Head and Neck Cancer Market
完整報告名稱與涵蓋範圍
Head and Neck Cancer Market Size, Share & Trends Analysis Report By Products (Cytotoxic Agents, Antimetabolites, Abitrexate/ Mexate/ Folex (methotrexate), Hydrea (hydroxyurea), Antitubulins, Others), By Region, And Segment Forecasts, 2025-2034
報告摘要
The global Head and Neck Cancer Market is poised to witness meaningful expansion over the coming years.
The Head and Neck Cancer sector involves sixth most common cancer worldwide, with an estimated 630,000 new cases every year. This domain has witnessed meaningful transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is supported by escalating healthcare spending, technological evolution, and the escalating focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell Head and Neck Cancer Market Snapshot
Chapter 4. Global Cell Head and Neck Cancer Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Clinical Trial/Pipeline Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 3: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Cytotoxic Agents
5.2.1.1. Antimetabolites
5.2.1.1.1. Abitrexate/ Mexate/ Folex (methotrexate)
5.2.1.1.2. Hydrea (hydroxyurea)
5.2.1.2. Antitubulins
5.2.1.2.1. Taxotere (docetaxel)
5.2.1.3. Others (Platinum Agents, Fluoropyrimidines)
5.2.1.3.1. Platinol (cisplatin)
5.2.1.3.2. 5-fluorouracil (5-FU)
5.2.2. EGFR Inhibitors (mAbs)
5.2.2.1. Erbitux (cetuximab)
5.2.2.2. Vectibix (panitumumab)
5.2.2.3. Theracim/Theraloc (nimotuzumab)
5.2.3. EGFR Inhibitors (TKIs)
5.2.3.1. Tarceva (erlotinib)
5.2.3.1.1. Iressa (gefitinib)
5.2.3.2. Tykerb/Tyverb (lapatinib)
5.2.4. PD1 Inhibitors
5.2.4.1. Keytruda (pembrolizumab)
5.2.4.2. Opdivo (nivolumab)
5.2.5. Pipeline Drugs (Late-stage)
5.2.5.1. EGFR Inhibitors (mAbs)
5.2.5.1.1. Vectibix (panitumumab)
5.2.5.2. PDL1 Inhibitors
5.2.5.2.1. Imfinzi (durvalumab)
5.2.5.2.2. Bavencio (avelumab)
5.2.5.3. CTLA4 Inhibitors
5.2.5.3.1. Yervoy (ipilimumab)
5.2.5.3.2. Tremelimumab
Chapter 6. Cell Head and Neck Cancer Market Segmentation 5: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
6.1.2. North America Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
6.2. Europe
6.2.1. Europe Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.2.2. Europe Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
6.3. Asia Pacific
6.3.1. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.3.2. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts by Types, 2021-2034
6.3.3. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
6.4. Latin America
6.4.1. Latin America Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.4.2. Latin America Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
6.5. Middle East & Africa
6.5.1. Middle East & Africa Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.5.2. Middle East & Africa Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Advaxis, Inc.
7.2.2. Amgen, Inc.
7.2.3. AstraZeneca plc
7.2.4. Boehringer Ingelheim GmbH
7.2.5. Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.)
7.2.6. Cel-Sci Corporation
7.2.7. Five Prime Therapeutics, Inc.
7.2.8. GlaxoSmithKline plc
7.2.9. Incyte Corporation
7.2.10. IRX Therapeutics, Inc.
7.2.11. MacroGenics, Inc.
7.2.12. Merck KGaA
7.2.13. Novartis AG
7.2.14. Pfizer, Inc.
7.2.15. Roche Holdings AG (Genentech)
7.2.16. Viracta Therapeutics
7.2.17. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們